Status:
COMPLETED
Investigation of Nickel Sensitization After Percutaneous Implantation of Patent Foramen Ovale Occluder
Lead Sponsor:
National and Kapodistrian University of Athens
Conditions:
Foramen Ovale, Patent
Nickel Sensitivity
Eligibility:
All Genders
14+ years
Phase:
NA
Brief Summary
Percutaneous PFO closure has been established as a first-line therapy for preventing recurrent strokes in selected patients. The devices used for the specific purpose contain and release nickel, which...
Detailed Description
Percutaneous PFO closure has been established as a first-line therapy for preventing recurrent strokes, after embolic stroke of unknown source (ESUS) and a patent foramen ovale. The PFO closure is ach...
Eligibility Criteria
Inclusion
- Age: at least 14 years old
- Well-documented indication for percutaneous PFO closure
Exclusion
- Corticosteroid treatment
- Patient's refusal to participation
Key Trial Info
Start Date :
December 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04713683
Start Date
December 10 2020
End Date
December 1 2024
Last Update
February 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Department of Cardiology, National and Kapodistrian University of Athens, Hippokration General Hospital of Athens
Athens, Attica, Greece, 115 28